Ranibizumab

Red

Brand Name(s):Lucentis

Indication:Neovascular (wet) age-related macular degeneration and macular oedema secondary to retinal vein occlusion

Rationale:1,2,8

Considered:Oct-06

Review Date:Jan-22

Comments:
NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

– details can be found at:tp://www.nice.org.uk/nicemedia/live/14305/65827/65827.pdf
Nov 2013